IP Library › Granted Patent US 12,622,889
Granted Patent B2
US 12,622,889 · App. 19/315,079 · Granted May 12, 2026

S-β-hydroxybutyrate esters for improving metabolic function

Inventors: Gary Millet (Washington, UT); Ryan Lowery (Tampa, FL); Jacob Wilson (Tampa, FL); Terry Lacore (Melissa, TX)
Assignee: AXCESS GLOBAL SCIENCES, LLC
A61K31/22A61K9/0053A61K31/047A61K31/19A23V2200/3322
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,622,889
App. No.
19/315,079
Granted
May 12, 2026
Kind
B2
Abstract

Compositions for improving metabolic function in a subject include optically pure S-beta-hydroxybutyrate or non-racemic mixtures enriched with the S-enantiomer. S-beta-hydroxybutyrate in pure or enriched form provides energy to the heart, dilates the arteries, decreases blood pressure and systemic vascular resistance, and increases cardiac output. S-Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. S-Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and provide one or more electrolytes. S-Beta-hydroxybutyrate esters provide more controlled release without adding electrolytes. Compositions for improving heart function in a subject may contain a dietetically or pharmaceutically acceptable carrier and optically pure S-beta-hydroxybutyrate or non-racemic mixture enriched with S-beta-hydroxybutyrate, wherein the compositions contain from about 50.5% to 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and from about 49.5% to 0% by enantiomeric equivalents of R-beta-hydroxybutyrate.

Claims (27)

1 . A composition for improving metabolic function in a subject, comprising:

one or more esters of optically pure S-beta-hydroxybutyrate or one or more esters of a non-racemic mixture of S-beta-hydroxybutyrate and R-beta-hydroxybutyrate containing more than 50% and less than 100% by enantiomeric equivalents of at least one S-beta-hydroxybutyrate ester and less than 50% and more than 0% by enantiomeric equivalents of at least one R-beta-hydroxybutyrate ester.

2 . The composition of claim 1 , wherein the composition comprises one or more esters of S-beta-hydroxybutyrate and at least one component selected from the group consisting of ethanol, 1-propanol, 1,2-propanediol, 1,3-propanediol, 1,3-butanediol, glycerin, S-beta-hydroxybutyrate R-beta-hydroxybutyrate, acetoacetate, dimers, trimers, oligomers, or polyesters containing repeating units of beta-hydroxybutyrate, and complex oligomers or polymers of beta-hydroxybutyrate and one or more carboxylic acids selected from lactic acid, citric acid, quinic acid, shikimic acid, salicylic acid, tartaric acid, malic acid, succinic acid, and fumaric acid.

3 . The composition of claim 1 , wherein the composition comprises one or more esters of S-beta-hydroxybutyrate and at least one component selected from the group consisting of altrose, arabinose, dextrose, erythrose, fructose, galactose, glucose, glycerol, gulose, idose, lactose, lyxose, mannose, ribitol, ribose, ribulose, sucrose, talose, threose, xylitol, xylose, galactosamine, glucosamine, mannosamine, N-acetylglucosamine, mannitol, sorbitol, and threitol.

4 . The composition of claim 1 , wherein the composition comprises a mixture of S-beta-hydroxybutyrate ester and at least one of S-beta-hydroxybutyric acid or S-beta-hydroxybutyrate salt.

5 . The composition of claim 1 , wherein the composition comprises a non-racemic mixture that contains 50.5% to 99.5% by enantiomeric equivalents of S-beta-hydroxybutyrate ester and 49.5% to 0.5% by enantiomeric equivalents of R-beta-hydroxybutyrate ester, or 51% to 99% by enantiomeric equivalents of S-beta-hydroxybutyrate ester and 49% to 1% by enantiomeric equivalents of R-beta-hydroxybutyrate ester, or 52% to 98% by enantiomeric equivalents of S-beta-hydroxybutyrate ester and 48% to 2% by enantiomeric equivalents of R-beta-hydroxybutyrate ester.

6 . The composition of claim 1 , further comprising an ester of optically pure S-1,3-butanediol or an ester of a non-racemic mixture enriched with S-1,3-butanediol relative to R-1,3-butanediol.

7 . The composition of claim 1 , wherein the composition further comprises at least one medium chain fatty acid having 6 to 12 carbons or ester thereof.

8 . The composition of claim 1 , wherein the composition further comprises at least one short chain fatty acid having less than 6 carbons, or a mono-, di- or triglyceride of the at least one short chain fatty acid.

9 . The composition of claim 1 , wherein the composition improves brain function in the subject.

10 . The composition of claim 1 , wherein the composition improves heart function in the subject.

11 . The composition of claim 1 , wherein the composition improves organ function in the subject.

12 . A kit for administering the composition of claim 1 to a subject, comprising:

a container in which the composition is placed, wherein the container is selected from the group consisting of carton, box, can, jar, bag, pouch, bottle, jug, liquid squeeze bottle with integrated measuring device, and keg; and

a measuring device configured to hold therein a unit dose, or fraction thereof, of the composition, wherein the measuring device is selected from the group consisting of cup, scoop, syringe, dropper, spatula, spoon, and colonic irrigation device.

13 . A composition for improving metabolic function in a subject, comprising:

one or more esters of optically pure S-beta-hydroxybutyrate or one or more esters of a non-racemic mixture of S-beta-hydroxybutyrate and R-beta-hydroxybutyrate containing more than 50% and less than 100% by enantiomeric equivalents of at least one S-beta-hydroxybutyrate ester and less than 50% and more than 0% by enantiomeric equivalents of at least one R-beta-hydroxybutyrate ester,

wherein the composition is provided as or in a tablet, capsule, powder, food product, food additive, flavored beverage, vitamin fortified beverage, non-alcoholic beverage, flavored beverage additive, vitamin fortified beverage additive, non-alcoholic beverage additive, candy, sucker, pastille, food supplement, flavored mouth spray, or suppository.

14 . The composition of claim 13 , wherein the composition comprises one or more esters of S-beta-hydroxybutyrate and at least one component selected from the group consisting of ethanol, 1-propanol, 1,2-propanediol, 1,3-propanediol, 1,3-butanediol, glycerin, S-beta-hydroxybutyrate R-beta-hydroxybutyrate, acetoacetate, dimers, trimers, oligomers, or polyesters containing repeating units of beta-hydroxybutyrate, and complex oligomers or polymers of beta-hydroxybutyrate and one or more carboxylic acids selected from lactic acid, citric acid, quinic acid, shikimic acid, salicylic acid, tartaric acid, malic acid, succinic acid, and fumaric acid.

15 . The composition of claim 13 , wherein the composition comprises one or more esters of S-beta-hydroxybutyrate and at least one component selected from the group consisting of altrose, arabinose, dextrose, erythrose, fructose, galactose, glucose, glycerol, gulose, idose, lactose, lyxose, mannose, ribitol, ribose, ribulose, sucrose, talose, threose, xylitol, xylose, galactosamine, glucosamine, mannosamine, N-acetylglucosamine, mannitol, sorbitol, and threitol.

16 . The composition of claim 13 , wherein the composition improves metabolic function of at least one of the subject's brain, heart, or other organ.

17 . A composition for improving metabolic function in a subject, comprising:

a dietetically or pharmaceutically acceptable carrier selected from the group consisting of tablet, capsule, powder, food product, food additive, flavored beverage, vitamin fortified beverage, non-alcoholic beverage, flavored beverage additive, vitamin fortified beverage additive, non-alcoholic beverage additive, candy, sucker, pastille, food supplement, flavored mouth spray, and suppository; and

one or more esters of optically pure S-beta-hydroxybutyrate or one or more esters of a non-racemic mixture of S-beta-hydroxybutyrate and R-beta-hydroxybutyrate containing more than 50% and less than 100% by enantiomeric equivalents of at least one S-beta-hydroxybutyrate ester and less than 50% and more than 0% by enantiomeric equivalents of at least one R-beta-hydroxybutyrate ester.

18 . The composition of claim 17 , wherein the composition comprises one or more esters of S-beta-hydroxybutyrate and at least one component selected from the group consisting of ethanol, 1-propanol, 1,2-propanediol, 1,3-propanediol, 1,3-butanediol, glycerin, S-beta-hydroxybutyrate R-beta-hydroxybutyrate, acetoacetate, dimers, trimers, oligomers, or polyesters containing repeating units of beta-hydroxybutyrate, and complex oligomers or polymers of beta-hydroxybutyrate and one or more carboxylic acids selected from lactic acid, citric acid, quinic acid, shikimic acid, salicylic acid, tartaric acid, malic acid, succinic acid, and fumaric acid.

19 . The composition of claim 17 , wherein the composition comprises one or more esters of S-beta-hydroxybutyrate and at least one component selected from the group consisting of altrose, arabinose, dextrose, erythrose, fructose, galactose, glucose, glycerol, gulose, idose, lactose, lyxose, mannose, ribitol, ribose, ribulose, sucrose, talose, threose, xylitol, xylose, galactosamine, glucosamine, mannosamine, N-acetylglucosamine, mannitol, sorbitol, and threitol.

20 . The composition of claim 17 , wherein the composition improves metabolic function of at least one of the subject's brain, heart, or other organ.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2025
From: MILLET, GARY; LOWERY, RYAN; WILSON, JACOB; LACORE, TERRY
To: AXCESS GLOBAL SCIENCES, LLC
Reel/Frame 072897/0717 →
Continuity (17)
Continuation In Part 19221260 · May 28, 2025
Continuation In Part 19096389 · Mar 31, 2025
Continuation 18977541 · Dec 11, 2024
Continuation 18592262 · Feb 29, 2024
Continuation 18219556 · Jul 7, 2023
Continuation In Part 18218519 · Jul 5, 2023
Continuation In Part 17555724 · Dec 20, 2021
Continuation 17367206 · Jul 2, 2021
Continuation 17130498 · Dec 22, 2020
Continuation In Part 16783886 · Feb 6, 2020
Continuation In Part 16272192 · Feb 11, 2019
Continuation In Part 16224485 · Dec 18, 2018
Division 15936849 · Mar 27, 2018
Continuation In Part 15491924 · Apr 19, 2017
Provisional Application 62607578 · Dec 19, 2017
Provisional Application 62324798 · Apr 19, 2016
Related Publication 20250381162A1 · Dec 18, 2025
References Cited (400)
US 2238149A · Aeckerle · 1941 [cited by applicant]
US 2976073A · Russell et al. · 1961 [cited by applicant]
US 4139761A · Obrowski · 1979 [cited by applicant]
US 4224503A · Gijzel et al. · 1980 [cited by applicant]
US 4292499A · Kleinschmidt et al. · 1981 [cited by applicant]
US 4627808A · Hughes · 1986 [cited by applicant]
US 4771074A · Lammerant et al. · 1988 [cited by applicant]
US 4969393A · Mahlich et al. · 1990 [cited by applicant]
US 4997976A · Brunengraber et al. · 1991 [cited by applicant]
US 5093044A · Wretlind et al. · 1992 [cited by applicant]
US 5100677A · Veech · 1992 [cited by applicant]
US 5116868A · Chen et al. · 1992 [cited by applicant]
US 5288512A · Seiden · 1994 [cited by applicant]
US 5292774A · Hiraide et al. · 1994 [cited by applicant]
US 5654266A · Chen et al. · 1997 [cited by applicant]
US 5700670A · Yamagishi et al. · 1997 [cited by applicant]
US 6031000A · Nissen et al. · 2000 [cited by applicant]
US 6207856B1 · Veech · 2001 [cited by applicant]
US 6217915B1 · Luchansky et al. · 2001 [cited by applicant]
US 6232345B1 · Hiraide et al. · 2001 [cited by applicant]
US 6316038B1 · Veech · 2001 [cited by applicant]
US 6323237B1 · Veech · 2001 [cited by applicant]
US 6380244B2 · Martin et al. · 2002 [cited by applicant]
US 6613356B1 · Vlahakos · 2003 [cited by applicant]
US 6706756B1 · Fitzpatrick et al. · 2004 [cited by applicant]
US 6835750B1 · Henderson · 2004 [cited by applicant]
US 7351736B2 · Veech · 2008 [cited by applicant]
US 7807718B2 · Hashim et al. · 2010 [cited by applicant]
US 7891287B2 · Miller · 2011 [cited by applicant]
US 8071641B2 · Weiss et al. · 2011 [cited by applicant]
US 8101653B2 · Veech · 2012 [cited by applicant]
US 8124589B2 · Henderson · 2012 [cited by applicant]
US 8344896B2 · Ozanne · 2013 [cited by applicant]
US 8426468B2 · Henderson · 2013 [cited by applicant]
US 8642654B2 · Clarke et al. · 2014 [cited by applicant]
US 8748400B2 · Henderson · 2014 [cited by applicant]
US 9138420B2 · D'Agostino et al. · 2015 [cited by applicant]
US 9186340B2 · Andrews et al. · 2015 [cited by applicant]
US 9211275B2 · Clarke et al. · 2015 [cited by applicant]
US 9435566B2 · Hill et al. · 2016 [cited by applicant]
US 9675577B2 · D'Agostino et al. · 2017 [cited by applicant]
US 9717767B2 · Carpenter et al. · 2017 [cited by applicant]
US 9795580B2 · Weeber et al. · 2017 [cited by applicant]
US 9808481B2 · Ritter et al. · 2017 [cited by applicant]
US 9925164B1 · Hashim · 2018 [cited by applicant]
US 9957246B2 · Stinchcomb et al. · 2018 [cited by applicant]
US 10022409B2 · Carpenter et al. · 2018 [cited by applicant]
US 10051880B2 · Clarke et al. · 2018 [cited by applicant]
US 10088197B2 · Hamagami et al. · 2018 [cited by applicant]
US 10245242B1 · Millet · 2019 [cited by applicant]
US 10245243B1 · Millet · 2019 [cited by applicant]
US 10278961B2 · Lowery et al. · 2019 [cited by applicant]
US 10292592B2 · Marshall et al. · 2019 [cited by applicant]
US 10292952B2 · Millet · 2019 [cited by applicant]
US 10407331B2 · Kamito et al. · 2019 [cited by applicant]
US 10512615B1 · Millet · 2019 [cited by applicant]
US 10588876B2 · Millet · 2020 [cited by examiner]
US 10588877B2 · Arnold · 2020 [cited by applicant]
US 10596128B2 · Millet · 2020 [cited by applicant]
US 10596129B2 · Millet · 2020 [cited by applicant]
US 10596130B2 · Millet · 2020 [cited by applicant]
US 10596131B2 · Millet · 2020 [cited by applicant]
US 10660958B2 · Clarke · 2020 [cited by applicant]
US 10736861B2 · Millet · 2020 [cited by applicant]
US 10792269B2 · Hashim · 2020 [cited by applicant]
US 10925843B2 · Millet · 2021 [cited by applicant]
US 10973786B2 · Millet · 2021 [cited by applicant]
US 10973792B2 · Millet · 2021 [cited by examiner]
US 10980764B1 · D'Agostino et al. · 2021 [cited by applicant]
US 10980772B2 · Millet · 2021 [cited by applicant]
US 11020362B2 · Millet · 2021 [cited by applicant]
US 11026929B2 · Lowery et al. · 2021 [cited by applicant]
US 11033553B2 · Millet · 2021 [cited by applicant]
US 11103470B2 · Millet · 2021 [cited by applicant]
US 11129802B2 · Millet · 2021 [cited by applicant]
US 11173138B2 · Lowery et al. · 2021 [cited by applicant]
US 11185518B2 · Millet · 2021 [cited by applicant]
US 11202769B2 · Millet · 2021 [cited by applicant]
US 11241403B2 · Millet · 2022 [cited by applicant]
US 11419836B2 · Millet · 2022 [cited by examiner]
US 11690817B2 · Millet · 2023 [cited by applicant]
US 11793778B2 · Millet · 2023 [cited by applicant]
US 11806324B2 · Millet · 2023 [cited by applicant]
US 11944598B2 · Millet · 2024 [cited by applicant]
US 11950616B2 · Millet · 2024 [cited by applicant]
US 12329734B2 · Millet · 2025 [cited by examiner]
US 20010014696A1 · Veech · 2001 [cited by applicant]
US 20010018866A1 · Fischer · 2001 [cited by applicant]
US 20010041736A1 · Veech · 2001 [cited by applicant]
US 20020013339A1 · Martin et al. · 2002 [cited by applicant]
US 20020124370A1 · Deckert et al. · 2002 [cited by applicant]
US 20030022937A1 · Veech · 2003 [cited by applicant]
US 20040126366A1 · Kaddurah-Daouk et al. · 2004 [cited by applicant]
US 20040138293A1 · Werner et al. · 2004 [cited by applicant]
US 20040266872A1 · Veech · 2004 [cited by applicant]
US 20050129783A1 · Mccleary et al. · 2005 [cited by applicant]
US 20050169968A1 · Elmaleh et al. · 2005 [cited by applicant]
US 20060165777A1 · Solomon et al. · 2006 [cited by applicant]
US 20060275253A1 · Ushida et al. · 2006 [cited by applicant]
US 20070029913A1 · Chen · 2007 [cited by applicant]
US 20070135376A1 · Henderson · 2007 [cited by applicant]
US 20070179197A1 · Henderson · 2007 [cited by applicant]
US 20080058416A1 · Greenwood et al. · 2008 [cited by applicant]
US 20080287372A1 · Henderson · 2008 [cited by applicant]
US 20090131475A1 · Uesugi et al. · 2009 [cited by applicant]
US 20090253781A1 · Veech · 2009 [cited by applicant]
US 20090306221A1 · Guy et al. · 2009 [cited by applicant]
US 20090325984A1 · Costentin et al. · 2009 [cited by applicant]
US 20100041751A1 · Henderson · 2010 [cited by applicant]
US 20100056631A1 · Hisamura et al. · 2010 [cited by applicant]
US 20100113494A1 · Hu et al. · 2010 [cited by applicant]
US 20100197758A1 · Andrews et al. · 2010 [cited by applicant]
US 20100210726A1 · Kuriyama · 2010 [cited by applicant]
US 20100298294A1 · Clarke et al. · 2010 [cited by applicant]
US 20110111049A1 · Andrews et al. · 2011 [cited by applicant]
US 20110237666A1 · Clarke et al. · 2011 [cited by applicant]
US 20110287114A1 · Johnson · 2011 [cited by applicant]
US 20120053240A1 · Rathmacher et al. · 2012 [cited by applicant]
US 20120071548A1 · Veech · 2012 [cited by applicant]
US 20120171165A1 · Buck et al. · 2012 [cited by applicant]
US 20120202891A1 · Stinchcomb et al. · 2012 [cited by applicant]
US 20130079406A1 · Veech · 2013 [cited by applicant]
US 20130337116A1 · Petralia · 2013 [cited by applicant]
US 20140256808A1 · Henderson · 2014 [cited by applicant]
US 20140329893A1 · Veech · 2014 [cited by applicant]
US 20140350105A1 · D'Agostino et al. · 2014 [cited by applicant]
US 20140352728A1 · Svensson · 2014 [cited by applicant]
US 20150018415A1 · Veech · 2015 [cited by applicant]
US 20150063140A1 · Yi et al. · 2015 [cited by applicant]
US 20150065571A1 · Clarke et al. · 2015 [cited by applicant]
US 20150132280A1 · Lopez et al. · 2015 [cited by applicant]
US 20150144074A1 · Fujimoto et al. · 2015 [cited by applicant]
US 20150320809A1 · Carpenter et al. · 2015 [cited by applicant]
US 20150363750A1 · Svensson et al. · 2015 [cited by applicant]
US 20160193173A1 · Clarke et al. · 2016 [cited by applicant]
US 20160256411A1 · Aung-Din · 2016 [cited by applicant]
US 20160263071A1 · Borges et al. · 2016 [cited by applicant]
US 20160272603A1 · Kravchenko et al. · 2016 [cited by applicant]
US 20170020844A1 · Galinski · 2017 [cited by applicant]
US 20170029650A1 · Veling et al. · 2017 [cited by applicant]
US 20170172969A1 · D'Agostino et al. · 2017 [cited by applicant]
US 20170258745A1 · Millet · 2017 [cited by applicant]
US 20170266148A1 · D'Agostino et al. · 2017 [cited by applicant]
US 20170290792A1 · Cavaleri · 2017 [cited by applicant]
US 20170296501A1 · Lowery et al. · 2017 [cited by applicant]
US 20170296520A1 · Lowery et al. · 2017 [cited by applicant]
US 20170298339A1 · Hanson et al. · 2017 [cited by applicant]
US 20170304564A1 · Dehaan et al. · 2017 [cited by applicant]
US 20180020699A1 · Steup · 2018 [cited by applicant]
US 20180021274A1 · Arnold · 2018 [cited by applicant]
US 20180021281A1 · Berger · 2018 [cited by applicant]
US 20180055797A1 · Llosa et al. · 2018 [cited by applicant]
US 20180057846A1 · Llosa et al. · 2018 [cited by applicant]
US 20180195096A1 · Veech et al. · 2018 [cited by applicant]
US 20180214399A1 · Spector et al. · 2018 [cited by applicant]
US 20180238586A1 · Sugatani et al. · 2018 [cited by applicant]
US 20190099394A1 · Ari et al. · 2019 [cited by applicant]
US 20190151267A1 · Millet · 2019 [cited by applicant]
US 20190167613A1 · Millet · 2019 [cited by applicant]
US 20190167614A1 · Millet · 2019 [cited by applicant]
US 20190177673A1 · Llosa et al. · 2019 [cited by applicant]
US 20190183220A1 · Takada · 2019 [cited by applicant]
US 20190183820A1 · Millet · 2019 [cited by applicant]
US 20190183821A1 · Millet · 2019 [cited by applicant]
US 20190191755A1 · Garvey et al. · 2019 [cited by applicant]
US 20190209501A1 · Tinsley et al. · 2019 [cited by applicant]
US 20190255028A1 · Lowery et al. · 2019 [cited by applicant]
US 20190262293A1 · Millet · 2019 [cited by applicant]
US 20190313682A1 · Nagel · 2019 [cited by applicant]
US 20190321309A1 · Millet · 2019 [cited by applicant]
US 20200030266A1 · Bradley et al. · 2020 [cited by applicant]
US 20200061004A1 · Millet · 2020 [cited by applicant]
US 20200078973A1 · Valeze et al. · 2020 [cited by applicant]
US 20200129463A1 · Lowery et al. · 2020 [cited by applicant]
US 20200140371A1 · Verdin et al. · 2020 [cited by applicant]
US 20200170982A1 · Millet · 2020 [cited by applicant]
US 20200253909A1 · Millet · 2020 [cited by applicant]
US 20200268701A1 · D'Agostino et al. · 2020 [cited by applicant]
US 20210095867A1 · Gururaja et al. · 2021 [cited by applicant]
US 20210106168A1 · Cingolani et al. · 2021 [cited by applicant]
US 20210205241A1 · Millet · 2021 [cited by applicant]
US 20220133673A1 · Millet · 2022 [cited by applicant]
US 20220202760A1 · Greenwood et al. · 2022 [cited by applicant]
US 20230072854A1 · Purpura et al. · 2023 [cited by applicant]
US 20230115966A1 · Wells et al. · 2023 [cited by applicant]
US 20230201145A1 · Millet · 2023 [cited by applicant]
US 20240024265A1 · Millet · 2024 [cited by applicant]
US 20240197668A1 · Millet · 2024 [cited by applicant]
US 20250288550A1 · Millet · 2025 [cited by examiner]
CA 2990927A1 · 2018 [cited by applicant]
CN 86108978A · 1987 [cited by applicant]
CN 1256629A · 2000 [cited by applicant]
CN 1347319A · 2002 [cited by applicant]
CN 1104978C · 2003 [cited by applicant]
CN 1184978C · 2005 [cited by applicant]
CN 1972698A · 2007 [cited by applicant]
CN 101674730A · 2010 [cited by applicant]
CN 101678043A · 2010 [cited by applicant]
CN 101969769A · 2011 [cited by applicant]
CN 102164884A · 2011 [cited by applicant]
CN 104224823A · 2014 [cited by applicant]
CN 105050594A · 2015 [cited by applicant]
CN 106038532A · 2016 [cited by applicant]
CN 106459646A · 2017 [cited by applicant]
CN 106858066A · 2017 [cited by applicant]
CN 108253621A · 2018 [cited by applicant]
CN 109480284A · 2019 [cited by applicant]
CN 111655244A · 2020 [cited by applicant]
CN 111867576A · 2020 [cited by applicant]
CN 112262936A · 2021 [cited by applicant]
DE 102017210992A1 · 2019 [cited by applicant]
EP 0008700A1 · 1980 [cited by applicant]
EP 1112711A1 · 2001 [cited by applicant]
EP 1178748A1 · 2002 [cited by applicant]
EP 1827412A1 · 2007 [cited by applicant]
EP 1915144A2 · 2008 [cited by applicant]
EP 2283834A2 · 2011 [cited by applicant]
EP 1755743B1 · 2013 [cited by applicant]
EP 2976073A1 · 2016 [cited by applicant]
EP 3094321A1 · 2016 [cited by applicant]
EP 3366173A2 · 2018 [cited by applicant]
EP 3446045A1 · 2019 [cited by applicant]
FR 2997302A1 · 2014 [cited by applicant]
GB 2391493A · 2004 [cited by applicant]
ID 201701176 · 2017 [cited by applicant]
JP 11060434A · 1999 [cited by applicant]
JP 2002521330A · 2002 [cited by applicant]
JP 2004035417A · 2004 [cited by applicant]
JP 5030553B2 · 2012 [cited by applicant]
JP 2015042644A · 2015 [cited by applicant]
JP 5690261B2 · 2015 [cited by applicant]
JP 2015514104A · 2015 [cited by applicant]
JP 2015102323A · 2015 [cited by applicant]
JP 2016514725A · 2016 [cited by applicant]
JP 2016121128A · 2016 [cited by applicant]
JP 2017046688A · 2017 [cited by applicant]
JP 2018158897A · 2018 [cited by applicant]
JP 2020502652A · 2020 [cited by applicant]
JP 2020527583A · 2020 [cited by applicant]
JP 2021504476A · 2021 [cited by applicant]
JP 2021506294A · 2021 [cited by applicant]
RU 2345546C2 · 2009 [cited by applicant]
WO 8703808A1 · 1987 [cited by applicant]
WO 9841200A1 · 1998 [cited by applicant]
WO 0004895A2 · 2000 [cited by applicant]
WO 0015216A1 · 2000 [cited by applicant]
WO 0069315A1 · 2000 [cited by applicant]
WO 0370823A2 · 2003 [cited by applicant]
WO 2005077348A1 · 2005 [cited by applicant]
WO 2005107724A1 · 2005 [cited by applicant]
WO 2006029577A1 · 2006 [cited by applicant]
WO 2006061624A1 · 2006 [cited by applicant]
WO 2007115282A2 · 2007 [cited by applicant]
WO 2007138322A1 · 2007 [cited by applicant]
WO 2008005818A1 · 2008 [cited by applicant]
WO 2008021394A2 · 2008 [cited by applicant]
WO 2008024408A2 · 2008 [cited by applicant]
WO 2009089144A1 · 2009 [cited by applicant]
WO 2010021766A1 · 2010 [cited by applicant]
WO 2010104595A1 · 2010 [cited by applicant]
WO 2011101171A1 · 2011 [cited by applicant]
WO 2012019295A1 · 2012 [cited by applicant]
WO 2012024611A1 · 2012 [cited by applicant]
WO 2013057506A1 · 2013 [cited by applicant]
WO 2013150153A1 · 2013 [cited by applicant]
WO 2014153415A2 · 2014 [cited by applicant]
WO 2014153416A1 · 2014 [cited by applicant]
WO 2015063140A1 · 2015 [cited by applicant]
WO 2015071811A1 · 2015 [cited by applicant]
WO 2015156865A1 · 2015 [cited by applicant]
WO 2016123229A1 · 2016 [cited by applicant]
WO 2016149687A1 · 2016 [cited by applicant]
WO 2017156446A1 · 2017 [cited by applicant]
WO 2017165443A1 · 2017 [cited by applicant]
WO 2017165445A1 · 2017 [cited by applicant]
WO 2017182664A1 · 2017 [cited by applicant]
WO 2017184788A1 · 2017 [cited by applicant]
WO 2017208217A2 · 2017 [cited by applicant]
WO 2018055388A1 · 2018 [cited by applicant]
WO 2018089863A1 · 2018 [cited by applicant]
WO 2018114309A1 · 2018 [cited by applicant]
WO 2018132189A1 · 2018 [cited by applicant]
WO 2018175879A1 · 2018 [cited by applicant]
WO 2018187324A1 · 2018 [cited by applicant]
WO 2018187852A1 · 2018 [cited by applicant]
WO 2019018683A1 · 2019 [cited by applicant]
WO 2019108683A1 · 2019 [cited by applicant]
WO 2019118624A1 · 2019 [cited by applicant]
WO 2019200132A1 · 2019 [cited by applicant]
WO 2019204148A1 · 2019 [cited by applicant]
WO 2019237152A1 · 2019 [cited by applicant]
WO 2019237185A1 · 2019 [cited by applicant]
WO 2020041871A1 · 2020 [cited by applicant]
WO 2020092451A1 · 2020 [cited by applicant]
WO 2021178547A1 · 2021 [cited by applicant]
WO 2022040644A2 · 2022 [cited by applicant]
Veech, “The Therapeutic Implications of Ketone Bodies: The Effects of Ketone Bodies in Pathological Conditions: Ketosis, Ketogenic Diet, Redox States, Insulin Resistance, and Mitochondrial Metabolism”, Prostaglandins Le… [cited by applicant]
Veech, et al., “Ketone Bodies Mimic the Life Span Extending Properties of Caloric Restriction”, IUBMB Life Feb. 8, 2017. [cited by applicant]
Vorgerd, M. and J. Zange. Treatment of glycogenosys type V (McArdle disease) with creatine and ketogenic diet with clinical scores and with 31P-MRS on working leg muscle. Acta Myologica, 2007; XXVI; pp. 61-63. [cited by applicant]
Walton, G. et al. A randomised, double-blind, placebo controlled cross-over study to determine the gastrointestinal effects of consumption of arabinoxylan-oligosaccharides enriched bread in healthy volunteers, 2012, Nut… [cited by applicant]
Wang et al. Eucommiae cortex polysaccharides attenuate gut microbiota dysbiosis and neuroinflammation. in mice exposed to chronic unpredictable mild stress: Beneficial in ameliorating depressive-like behaviors, 2024, Jo… [cited by applicant]
Williams et al., “The Chemistry of the Ketogenic Diet: Updates and Opportunities in Organic Synthesis”, Int J Mol Sci., May 15, 2021, vol. 22, No. 10, 5230, pp. 1-18. [cited by applicant]
WO2009045481, Pan et al. Published Apr. 9, 2009 Listed in this section as citation type “foreign” does not allow for any appropriate country code for “WO” documents. [cited by applicant]
Wu et al., “Medium-Chain Triglycerides in Infant Formulas and Their Relation to Plasma Ketone Body Concentrations,” Pediatric Research, vol. 20, No. 4, (1986), pp. 338-341. [cited by applicant]
Yang Y. et al., Role of Adherent-Invasive [cited by applicant]
Yang Yue et al., “Research on sarcopenic obesity”, Chinese Journal of Modern Medicine, vol. 20, No. 3, Mar. 25, 2018, pp. 98-101. [cited by applicant]
Yang Zeyi, “Biochemistry of sports nutrition scientific research progress”, Mar. 31, 2004, vol. 23, No. 2, pp. 158-165. [cited by applicant]
Zaleski, A. et al., Butyric acid in irritable bowel syndrome, 2013, Prz Gastroenterol, 8(6), 350-353 (Year: 2013). [cited by applicant]
Zeng Jing et al., “B-hydroxy-3-methyl—The clinical effects and mechanism”, vol. 2, No. 2, Jun. 9, 2015, pp. 57-62. [cited by applicant]
A New Toy Measuring Blood Ketones. Diet Doctor, Aug. 21, 2012. Dowloaded Apr. 1, 2015. http://www.dietdoctor.com/a-new-toy-measuring-blood-ketoones. [cited by applicant]
Allendorfer et al., “Neuroimaging studies towards understanding the central effects of pharmacological cannabis products on patients with epilepsy”, Epilepsy Behav, May 2017, vol. 70, pp. 349-354. [cited by applicant]
Amazon, “Perfect Keto Perform Pre Workout Powder—Bum Fat for Fuel Energy Supplement Drink Mix for Men and Women—Keto Friendly with Ketone Salts, BCAA, Nitric Oxide & MCT”, Sep. 25, 2017 entire document especially p. 1 R… [cited by applicant]
Anonymous: “Strawberry Pineapple Flavour Pre-Exertion Performance Optimizer”, Mintel, Database accession No. 5661617, 2018, pp. 4. [cited by applicant]
Arendash et al. “Caffeine and Coffee as Therapeutics Against Alzheimer's Disease”, Journal of Alzheimer's Disease 20, 2010, S117-S126. [cited by applicant]
Arnold, Instant Ketosis?, (2013), Aug. 4, 2013 (retrieved on Apr. 21, 2017), p. 1-3. Retrieved from the internet; URL: <http://patrickarnoldblog.com/instant-ketosis/. (Year: 2013). [cited by applicant]
Bala et al. Drug Invention Today. Jun. 1, 2018;10(6), 929-931. [cited by applicant]
Bastin et al., “Salt Slection and Optimisation Procedures for Pharmaceutical New Chemical Entities”, American Chemical Society and the Royal Society of Chemistry, vol. 4, No. 5, 2000, pp. 427-435. [cited by applicant]
Blazquez et al. Journal of Neurochemistry, 1999, vol. 72 No. 4, pp. 1759-1768. (Year: 1999). [cited by applicant]
Budin. N. et al., “Efficient synthesis of the ketone body ester (R)-3-hydroxybutyryl-(R)-3-hydroxybutyrate and its (S, S) enantiomer,” Bioorganic Chemistry, vol. 80, Oct. 2018, pp. 560-564. [cited by applicant]
Clarke, et al., Kinetics, safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects. Regul Toxicol Pharmacol. Aug. 2012; 63(3):401-8. [cited by applicant]
Craciun, S. et al. Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme, 2012, PNAS, 109(52): 21307-21312 (Year: 2012). [cited by applicant]
Cresci, G. et al., Lactobacillus GG and Tributyrin Supplementation Reduce Antibiotic-Induced Intestinal Injury, 2013, Journal of Parenteral and Enteral Nutrition, 37(6), 1-20 (Year: 2013). [cited by applicant]
Daniells, Stephen, ‘This is caffeine-evolved: Ingenious Ingredients co-founder talks up potential of paraxanthine,’ Nov. 3, 2021, 2 pages, retrieved from https://www.nutraingredients-usa.com/Article/2021/11/03/This-is-c… [cited by applicant]
Database GNPD Mintel, Sep. 29, 2016, anonymous, “Blue Lemon Ice Advanced Formula”, XP093048090, Database accession No. 4315637, pp. 3. [cited by applicant]
Decision to grant received for European Patent Application No. 17786592.0, mailed on Nov. 3, 2023, 2 pages. [cited by applicant]
Dedkova et al. “Role of B-hydroxybutyrate, its polymer poly-b-hydroxybutyrate and inorganic polyphosphate in mammalian health and disease”, Frontiers in Physiology, Jul. 17, 2014, pp. 1-22. [cited by applicant]
Dietary Guidelines Recommendations at https://health.gov/our-work/food-nutrition/2015-2020-dietary-guidelines/guidelines/ appendix-7/ (2010) (retrieved from the internet Oct. 20, 2020) (Year: 2010). [cited by applicant]
Dolson, Laura. How to Test Your Blood for Ketones. Downloaded Apr. 1, 2015. http://lowcarbdiets.about.com/od/KetogenicDiets/a/How-to-Test-Blood-For-Ketones.htm. [cited by applicant]
Energy Times—“Herbal Keto Support”, Jan. 15, 2008 (5 pages). [cited by applicant]
European Search Report received for EP Patent Application No. 19880284.5, mailed on Jul. 12, 2022, 11 pages. [cited by applicant]
European Search Report received for EP Patent Application No. 20755289.4, mailed on Oct. 11, 2022, 7 pages. [cited by applicant]
European Search Report received for EP Patent Application No. 20755994.9, mailed on Sep. 21, 2022, 6 pages. [cited by applicant]
European Search Report received for EP Patent Application No. 20805593.9, mailed on Dec. 16, 2022, 9 pages. [cited by applicant]
European Search Report received for EP Patent Application No. 21750261.6, mailed on Feb. 2, 2024, 10 pages. [cited by applicant]
European Search Report received for EP Patent Application No. 21862356.9, mailed on Jul. 1, 2024, 10 pages. [cited by applicant]
Extended European Search Report pursuant to Rule 62 EPC (EPO Form 1507S) issued on Jan. 24, 2017 for corresponding European Patent Application No. 14770025.6. [cited by applicant]
Extended European Search Report received for EP Patent Application No. 19788264.0, mailed on Dec. 20, 2021, 11 pages. [cited by applicant]
Extended European Search Report received for EP Patent Application No. 20755770.3, mailed on Sep. 1, 2022, 7 pages. [cited by applicant]
First Examination Report for New Zealand Patent Application No. 711433 issued by the New Zealand Intellectual Property Office dated Mar. 10, 2016. [cited by applicant]
First Office Action issued by the Chinese State Intellectual Property Office on Nov. 4, 2016 for corresponding Chinese Patent Application No. 201480016818.0. [cited by applicant]
Grootaert, C. Comparison of prebiotic effects of arabinoxylan oligosaccharides and inulin in a simulator of the human intestinal microbial ecosystem, 2009, FEMS Microbiology Ecology, 69: 231-242 (Year: 2009). [cited by applicant]
Haces M L et al: “Antioxidant capacity contributes to protection of ketone bodies against oxidative damage induced during hypoglycemic conditions”, Experimental Neurology, Elsevier, Amsterdam, NL, vol. 211, No. 1, May 1… [cited by applicant]
Hashim, Sami A., et al., “Ketone body therapy: from the ketogenic diet to the oral administration of ketone ester”, Journal of Lipid Research, vol. 55, 2014. [cited by applicant]
Haywood A, Glass BD. Pharmaceutical excipients—where do we begin? Australian Prescriber. 2011; 34: 112-114. [cited by applicant]
Henderson, Samuel T. “Ketone Bodies as a Therapeutic for Alzheimer's Disease.” Neurotherapeutics. Jul. 2008; 5(3):470-80. [cited by applicant]
Holscher, H. Dietary fiber and prebiotics and the gastrointestinal microbiota, 2017, Gut Microbes, 8(2): 172-184 (Year: 2017). [cited by applicant]
Holtzman et al., “Role of adenosine receptors in caffeine tolerance”, J. Pharmacol. Exp. Ther., 1991 ; 256(1 ):62-68. [cited by applicant]
Huang Dexiang et al., “Clinical Intravenous Nutrition”, Shanghai Medical University Press Jan. 31, 1994, pp. 121-124. [cited by applicant]
Ichim, T. et al., Experimental support for the effects of a probiotic/digestive enzyme supplement on serum cholesterol concentrations and the intestinal microbiome, 2016, Journal of Translational Medicine, 14(184), 1-9 … [cited by applicant]
Intention to grant received for European Patent Application No. 17786592.0, mailed on Jun. 27, 2023, 7 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US17/28465, mailed on Nov. 1, 2018, 7 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US17/28466, mailed on Nov. 1, 2018, 8 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US19/58676, mailed on May 14, 2021, 6 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US20/37289, mailed on Dec. 30, 2021, 6 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2014/031237, mailed on Oct. 1, 2015, 8 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2017/021886, mailed on Sep. 20, 2018, 9 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2018/062093, mailed on Jun. 4, 2020, 6 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2018/062096, mailed on Jul. 2, 2020, 8 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2019/027214, mailed on Oct. 29, 2020, 09 pages. [cited by applicant]
Luis Villasenor, “Supplements and Ketogenic Diets—Facts and Myths”, Retrieval from https://www.ketogains.com/2015/09/supplements-and-ketogenic-diets-facts-and-myths/, Sep. 18, 2015, pp. 15. [cited by applicant]
Lytra. G. et al., “Distribution and Organoleptic Impact of Ethyl 3-Hydroxybutanoate Enantiomers in Wine,” J. Agric. Food Chem, vol. 63, Issue 48, 2015, pp. 10484-10491. [cited by applicant]
Maalouf Met al., “Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation,” Neuroscience, New York, NY, US, vol. 145, Issue 1, Mar. … [cited by applicant]
Maalouf Met al., “The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies,” Brain Research Reviews, Elsevier, NL, vol. 59, No. 2, Mar. 1, 2009, pp. 293-315. [cited by applicant]
Maguire et al., “Gut dysbiosis, leaky gut, and intestinal epithelial proliferation in neurological disorders: towards the development of a new therapeutic using amino acids, prebiotics, probiotics, and postbiotics”, Rev… [cited by applicant]
Malo, M. S. et. al., Intestinal alkaline phosphatase preserves the normal homeostasis of gut microbiota, 2010, Gut, 59, 1476-1484 (Year: 2010). [cited by applicant]
Mangels D.R. et al, “Catechins as Potential Mediators of Cardiovascular Health”, Translational Sciences, vol. 37, No. 5, May 1, 2017, pp. 757-763. [cited by applicant]
McFarland, L. Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review, 2014, BMJ Open, 4(8): 1-18 (Year: 2014). [cited by applicant]
Murray, Andrew J., et al. “Novel ketone diet enhances physical and cognitive performance”, The FASEB Journal, No. Dec. 30, 2016. [cited by applicant]
National Center for Biotechnology Information. PubChem Compound Summary for CID 441, 3-Hydroxybutyric acid, https://pubchem.ncbi.nlm.nih.gov/compound/3-Hydroxybutyric-acid. (Year: 2005). [cited by applicant]
Newman et al., “B-hydroxybutyrate: Much more than a metabolite”, Diabetes Res Clin Pract., Nov. 2014. [cited by applicant]
Non-Final Rejection Mailed on Sep. 9, 2020 for U.S. Appl. No. 16/783,956. [cited by applicant]
Nova Max Plus Glucose and Ketone Testing with One Monitor. Downloaded Apr. 1, 2015. http://www.novacares.com/nova-max-plus/. [cited by applicant]
O'Mailey et al, Appl. Physiol. Nutr. Metab. 42: 1031-1035 (2017) Published at www.NRCRESEARCHPRESS.com/APNM on Jul. 27, 2017. [cited by applicant]
O'Meara, Cyndi, Changing Habits, Ketosis—Can we achieve it in a pill?, https://changinghabits. com.au/ketosis-can-we-achieve-it-in-a-pill/, 12 pages, (Jan. 13, 2017). [cited by applicant]
Office Action received for European Patent Application No. 17786592.0, mailed on Jun. 17, 2022, 7 pages. [cited by applicant]
Office Action received for European Patent Application No. 17786592.0, mailed on Sep. 25, 2020, 7 pages. [cited by applicant]
Office Action received for European Patent Application No. 19788264.0, mailed on Mar. 13, 2024, 5 pages. [cited by applicant]
Office Action received for European Patent Application No. 19880284.5, mailed on Nov. 9, 2023, 5 pages. [cited by applicant]
Office Action received for European Patent Application No. 20805593.9, mailed on Dec. 22, 2023, 7 pages. [cited by applicant]
Paraxanthine—Pubchem—2023 (Year: 2023). [cited by applicant]
Parker, Steve, “Ketogenic Mediterraanean Diet: Version 2.3,” Nov. 23, 2010, pp. 1-3. (Year: 2010). [cited by applicant]
Partial supplementary European search report (EPO Form 1507US) issued by the European Patent Office on Sep. 21, 2016 for corresponding European Application No. 14770025.6. [cited by applicant]
Pete J Cox et al, “Acute nutritional ketosis: implications for exercise performance and metabolism,” Extreme Physiology & Medicine, vol. 3, Issue 1, Dec. 1, 2014, pp. 1-9. [cited by applicant]
Precision Xtra vs. NovaMax Plus: Ketone Meter Evaluation. Jimmy Moore's Livin' La Vida Low Garb Blog. Downloaded Apr. 1, 2015. http://livinlavidalowcarb.com/blog/precision-xtra-vs-novamax-plus-ketone-meter-evaluation/15… [cited by applicant]
Pubchem, “Acetoacetic acid” Electronic Resource: https://pubchem.ncbi.nim.nih.gov/compound/Acetoacetic-acid, Retrieved on Sep. 3, 2019. [cited by applicant]
Rho et al. “Acetoacetate, Acetone, and Dibenzylamine (A Contaminant in L-(+)-Beta-Hydroxybutyrate) Exhibit Direct Anticonvulsant Actions In Vivo”, Epilepsia, Raven Press Ltd, New York, US, vol. 43, No. 4, Apr. 1, 2002 (… [cited by applicant]
Riccio et al. The human gut microbiota is neither an organ nor a commensal, 2020, FEBS Letters, 594(20): 3262-3271 (Year: 2020). [cited by applicant]
Rich A.J., “Ketone Bodies as Substrates,” Proceedings of the Nutrition Society (1990), vol. 49, 361-373. [cited by applicant]
Robson et al. Expert Opin. Drug Saf. (2011), vol. 10, pp. 675-685 (Year: 2011). [cited by applicant]
Roeder, Lois M., et al. The Effects of Ketone Bodies, Bicarbonate, and Calcium on Hepatic Mitochondrial Ketogenesis. Archives of Biochemistry and Biophysics, vol. 217, No. 2, Sep. pp. 460-467, 1982. [cited by applicant]
Rogers GB et al. From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways, 2016, Molecular Psychiatry, 21: 738-748 (Year: 2016). [cited by applicant]
Sajewicz et al. In Journal of Liquid Chromatography & Related Technologies, 33:1047-1057 (2010) (Year: 2010). [cited by applicant]
Sanchez, J. I. et al. Arabinoxylan-oligosaccharides (AXOS) affect the protein/carbohydrate fermentation balance and microbial population dynamics of the Simulator of Human Intestinal Microbial Ecosystem, 2009, Microbial… [cited by applicant]
Sara, How do you know which product is right for you? How to choose exogenous ketones, https://ketosupplements.co.uk/how-to-choose-exogenous-ketones/, 10 pages, (Sep. 25, 2017). [cited by applicant]
Search Report and Written Opinion issued by the Intellectual Property Office of Singapore on Apr. 18, 2016 for corresponding Singapore Application No. 11201506780R. [cited by applicant]
Serum Ketones Test. MedlinePlus Medical Encyclopedia. Downloaded Apr. 1, 2015. http://www.nlm.nih.gov/medlineplus/ency/article/003498.htm. [cited by applicant]
Shigeno et al. in Biosci. Biotech. Biochem., 56(2), 320-323 (1992) (Year: 1992). [cited by applicant]
Short, Jay, Effects of a Ketone/Caffeine Supplement on Cycling and Cognitive Performance, Master's thesis, Ohio State University, 61 pages, (Jan. 1, 2017). [cited by applicant]
Slavin, J. Fiber and Prebiotics: Mechanisms and Health Benefits, 2013, Nutrients, 5: 1417-1425 (Year: 2013). [cited by applicant]
Sorensen et al. (“Simultaneous determination of B-hydroxybutyrate and B-hydroxy-B-methylbutyrate in human whole blood using hydrophilic interaction liquid chromatography electrospray tandem mass spectrometry”, Clinical … [cited by applicant]